95% effective dose (ED95) of remazolam besylate for general anesthesia sedation in the frail or non-frail elderly

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200055290

Enrollment

Unknown

Registered

2022-01-05

Start date

2022-01-04

Completion date

Unknown

Last updated

2023-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

non-frality group:Intravenous remazolam

frality group:Intravenous remazolam

Eligibility

Sex/Gender

All

Age

65 Years to 95 Years

Inclusion criteria

Inclusion criteria: 1. Aged >= 65 years; 2. ASA classification I-III; 3. ''Non-cardiac, non-brain, non-transplant'' elective surgery under general anesthesia; 4. 18.5kg/m^2<BMI<23.9kg/m^2; 5. The patient himself or the authorized person signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with long-term use of sedative drugs; 2. Patients allergic to remazolam or propofol; 3. Patients with severe speech and audio-visual impairment; 4. Patients who refused to participate in this experiment.

Design outcomes

Primary

Measure	Time frame
time of loss of consicousness;	—

Secondary

Measure	Time frame
EEG Bispectral Index;non-invasive blood pressure;heart rate;respiratory rate;pulse oximetry;	—

Countries

China

Contacts

Public ContactWang Sicong

The Second Affiliated Hospital of Wenzhou Medical University

229500974@qq.com+86 13819711591

Outcome results